SELF-CERV Screening
The Minerva Project • January 23, 2026
Cervical cancer is one of the most preventable cancers. Yet, over 13,000 women are diagnosed every year in the U.S, and 1 in 4 women are not up-to-date on their screening for their cancer. A large reason for this is the apprehension many women feel towards the tools and procedures used in in-clinic screenings, like the pap smear, which can feel intimidating. However, recent innovations in technology and new policies are helping make this essential process more accessible.
Last May, the FDA approved the first at-home self-collection device for cervical cancer screening, called the Teal Wand. The samples are then sent to a lab where they are tested, and women can receive further support through a provided tele-health service from the comfort of their own home. The approval was backed by the SELF-CERV study, which showed that the self-collection method had the same detection performance as clinician-collected samples.
A few weeks ago, the U.S. Health and Human Services Department released guidelines approving self-collection samples as a way to test for HPV, the most common cause of cervical cancer. This means that most insurance providers will have to cover this form of testing starting in 2027, making cervical cancer screening more accessible to a wider range of people.
Cervical cancer screening procedures, especially pap smears, have barely changed since they became routine in the 1940s. The new technology, backed by government support, demonstrates how responsive innovation and policy-making can play a critical role in advancing women’s health. By addressing long-standing barriers in access to preventative care, healthcare not only becomes more effective by reaching those in need, but also more equitable.
